ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate -413.15% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -18.01
- INTEREST(HY) At HKD 3.25 MM has Grown at 19.49%
- ROCE(HY) Lowest at -17.49%
- PRE-TAX PROFIT(Q) At HKD -202.57 MM has Fallen at -146.5%
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 61.69%, its profits have risen by 47%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
-100.0%
2.89
63.10%
Hang Seng Hong Kong
8.25%
0.36
24.71%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
204.90%
EBIT Growth (5y)
-413.15%
EBIT to Interest (avg)
-18.01
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
0.06
Tax Ratio
87.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
20.23
EV to EBIT
-225.37
EV to EBITDA
-335.43
EV to Capital Employed
205.84
EV to Sales
32.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-91.33%
ROE (Latest)
-8.88%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
NET PROFIT(HY)
Higher at HKD -169.93 MM
RAW MATERIAL COST(Y)
Fallen by -12.23% (YoY
-11What is not working for the Company
INTEREST(HY)
At HKD 3.25 MM has Grown at 19.49%
ROCE(HY)
Lowest at -17.49%
PRE-TAX PROFIT(Q)
At HKD -202.57 MM has Fallen at -146.5%
NET PROFIT(Q)
At HKD -169.93 MM has Fallen at -151.46%
NET SALES(Q)
Fallen at -31.87%
Here's what is working for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Raw Material Cost
Fallen by -12.23% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at HKD 52.77 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (HKD MM)
Here's what is not working for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Pre-Tax Profit
At HKD -202.57 MM has Fallen at -146.5%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (HKD MM)
Net Profit
At HKD -169.93 MM has Fallen at -151.46%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (HKD MM)
Interest
At HKD 3.25 MM has Grown at 19.49%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (HKD MM)
Net Sales
Fallen at -31.87%
Year on Year (YoY)MOJO Watch
Near term sales trend is negative
Net Sales (HKD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
